Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for LARRY EDWARDS�
+1.81 (1.38%)
Dec 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 131.73 - 133.75
52 week 62.91 - 134.29
Open 132.14
Vol / Avg. 1.52M/944,711.00
Mkt cap 14.25B
P/E 18.49
Div/yield     -
EPS 7.20
Shares 106.90M
Beta 0.61
Inst. own 90%
Feb 2, 2015
Q4 2014 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 8, 2014
Edwards Lifesciences Corp Investor Conference
Nov 11, 2014
Edwards Lifesciences Corp at Credit Suisse Healthcare Conference
Oct 23, 2014
Q3 2014 Edwards Lifesciences Corp Earnings Call - Webcast
Oct 23, 2014
Q3 2014 Edwards Lifesciences Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 15.57% 19.15%
Operating margin 19.86% 25.19%
EBITD margin - 25.61%
Return on average assets 11.37% 15.84%
Return on average equity 19.17% 25.78%
Employees 8,600 -
CDP Score - -


One Edwards Way
IRVINE, CA 92614
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 52
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 57
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Valve Replacement
Age: 48
Bio & Compensation  - Reuters
Nicholas J. Valeriani Director
Age: 54
Bio & Compensation  - Reuters
Mike R. Bowlin Independent Director
Age: 71
Bio & Compensation  - Reuters
John T. Cardis Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert A. Ingram Independent Director
Age: 71
Bio & Compensation  - Reuters